Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system

Breast Cancer Research and Treatment

Volumn 87, Issue 3, 2004, Pages 255-264

  Günthert, Andreas R ^a   Gründker, Carsten ^a   Bongertz, Till ^a   Nagy, Attila ^b   Schally, Andrew V ^b   Emons, Günter ^a  

^a Germany ^*  (Germany)

^b TULANE UNIVERSITY   (United States)

Author keywords

AN 152; apoptosis; breast cancer; MDR 1; P glycoprotein

Indexed keywords

CARBOXYLESTERASE; DOXORUBICIN; DYFLOS; GENE PRODUCT; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FETAL CALF SERUM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; NEOPLASMS, HORMONE-DEPENDENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 8644219704     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-8806-8     Document Type: Article

References (35)

1. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989
2. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B: Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 25: 37-46, 1993
3. Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H, Sasano H: Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int 51: 333-337, 2001
4. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH-agonists. J Clin Endocrinol Metab 64: 425-432, 1987
5. 1 phase of the cell cycle. Br J Cancer 63: 930-932, 1991
6. Klijn JG: LH-RH agonists in the treatment of metastatic breast cancer: ten years' experience. Recent Results Cancer Res 124: 75-90, 1992
7. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV: Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 21: 35-45, 1992
8. Marini L, Iacopino F, Schinzari G, Robustelli della Cuna FS, Mantovani G, Sica G: Direct antiproliferative effect of triptorelin on human breast cancer cells. Anticancer Res 14: 1881-1885, 1994
9. Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 89: 2336-2339, 1992
10. Völker P, Gründker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186: 171-179, 2002
11. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD, Emons G: Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90: 552-559, 2003
12. Schally AV, Nagy A: New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72: 2305-2320, 2002
13. Emons G, Ortmann O, Schulz KD, Schally AV: Growth-inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab 8: 355-362, 1997
14. Schally AV: Luteinizing hormone-releasing hormone analogs; their impact on the control of tumorigenesis. Peptides 20: 1247-1262, 1999
15. Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN, Liebow C: Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res 60: 4194-4199, 2000
16. Halmos G, Nagy A, Lamharzi N, Schally AV: Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 136: 129-136, 1999
17. Wang X, Krebs LJ, Al-Nuri M, Pudavar HE, Ghosal S, Liebow C, Nagy AA, Schally AV, Prasad PN: A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci USA 96: 11081-11084, 1999
18. Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K: Targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anticancer Drugs 8: 974-987, 1997
19. Baja AM, Schally AV, Halmos G, Nagy A: Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9: 3742-3748, 2003
20. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. The Lancet 352: 930-942, 1998
21. Booser DJ, Hortobagyi GN: Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 47: 223-258, 1994
22. Zhang W, Ling V: Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 184: 17-26, 2000
23. Nagy A, Plonowski A, Schally AV: Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA 97: 829-834, 2000
24. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R et al.: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993
25. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz K-D, Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464, 1993
26. Völker P, Gründker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation and correlation with direct anti-proliferativer activity of LHRH analogues. Am J Obstet Gynecol 186: 171-179, 2002
27. Nicoletti I, Migloriati G, Pagliacci MC, Grignani F, Ricardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279, 1991
28. Nagy A, Schally AV, Armatis P, Szepeshazy K, Halmos G, Kovacs M et al.: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrollino-doxorubicin, a derivate 500-1000 times more potent. Proc Natl Acad Sci USA 93: 7269-7273, 1996
29. Chatzistamou I, Schally AV, Nagy A, Armatis P, Szepeshazi K. Halmos G: Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin Cancer Res 6: 4158-4165, 2000
30. Westphalen S, Kotulla G, Kaiser F, Krauß W, Werning G, Elsässer HP et al.: Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17: 1063-1069, 2000
31. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K et al.: Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89: 1803-1809, 1997
32. Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, Plonowski A: Targeting of doxorubicin bES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 19: 571-577, 2001
33. Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G: Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 187: 528-537, 2002
34. Letsch M, Schally AV, Szepeshazy K, Halmos G, Nagy A: Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 9: 4505-4513, 2003
35. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP: Levels of multi-drug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998